Enhanced Antitumor Activity for the Thymidylate Synthase Inhibitor 1843U89 through Decreased Host Toxicity with Oral Folic Acid

Cancer Research

Volumn 55, Issue 24, 1995, Pages 6117-6125

  Smith, Gary K ^a   Amyx, Herbert ^a   Boytos, Christine M ^a   Duch, David S ^a   Ferone, Robert ^a   Wilson, H Robert ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; ENZYME INHIBITOR; FOLIC ACID; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL METABOLISM; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITOR COMPLEX; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMAL; BODY WEIGHT; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FOLIC ACID; HUMAN; INDOLES; INTESTINAL DISEASES; LEUCOVORIN; MICE; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; QUINAZOLINES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0028789597     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Dev, I. K., Dallas, W. S., Ferone, R., Hanlon, M., McKee, D. D., and Yates, B. B. Mode of binding of folate analogs to thymidylate synthase: evidence for two asymmetric but interactive substrate binding sites. J. Biol. Chem., 269: 1873–1882, 1994.
2. Pendergast, W., Dickerson, S. H., Dev, I. K., Ferone, R., Duch, D. S., and Smith, G. K. Benzo[f]quinazoline inhibitors of thymidylate synthase: methyleneamino-linked arylglutamate derivatives. J. Med. Chem., 37: 838–844, 1994.
3. Duch, D. S., Banks, S. D., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., Humphreys, J., Knick, V., Pendergast, W., Singer, S., Smith, G. K., Waters, K., and Wilson, H. R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res., 53: 810–818, 1993.
4. Banks, S. D., Waters, K. A., Barrett, L. L., Dickerson, S., Pendergast, W., and Smith, G. K. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations. Cancer Chemother. Pharmacol., 33: 455–459, 1994.
5. Wilson, H. R., Heath, L. S., Knick, V. C., Koszalka, G. W., and Ferone, R. In vivo antitumor activity of 1843U89, a new antifolate thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res., 33: 407, 1992.
6. Wilson, H. R., Ferone, R., Boytos, C. M., Heath, L. S., Jones, W., Knick, V. C., and Waters, K. Enhanced 1843U89 in vivo activity by coadministration of methoxypolyethyleneglycol-thymidine Phosphorylase. Proc. Am. Assoc. Cancer Res., 36: 376, 1995.
7. Boytos, C. M., Ferone, R., Jones, W. A., Rudolph, S. K., Franklin, S. L., and Houle, C. D. In vivo antitumor activity of 1843U89 against experimental liver metastases in the nude mouse. Proc. Am. Assoc. Cancer Res., 36: 376, 1995.
8. Ferone, R., Hanlon, M. H., Waters, K. A., and Dev, I. K. Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89. Proc. Am. Assoc. Cancer Res., 34: 274, 1993.
9. Allegra, C. J. Antifolates. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 110–153. Philadelphia: J. B. Lippincott Co., 1990.
10. Pizzorno, G., Sokoloski, J. A., Cashmore, A. R., Moroson, B. A., Cross, A. D., and Beardsley, G. P. Intracellular metabolism of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid in human leukemic cell lines. Mol. Pharmacol., 39: 85–89, 1991.
11. Hanlon, M. H., Ferone, R., Mullin, R. J., and Keith, B. R. In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate and acyclic tetrahydrofolate analogue. Cancer Res., 50: 3207–3211, 1990.
12. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI Dl694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579–5586, 1991.
13. 10-propargyl-5,8-dideazafolic acid (CB 3717) in the rumour-bearing mouse. Anticancer Res., 8: 791–796, 1988.
14. 10-propargyl-5,8-dideazafolic acid (CB3717) polygluta-mates in LI210 cells in vitro. Biochem. Pharmacol., 37: 4047–4054, 1988.
15. Ward, W. H. J., Kimbell, R., and Jackman, A. L. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem. Pharmacol., 43: 2029–2031, 1992.
16. Keyomarsi, K., and Moran, R. G. Quinazoline folate analogs inhibit the catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate. J. Biol. Chem., 265: 19163–19169, 1990.
17. Habeck, L. L., Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., and Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res., 54: 1021–1026, 1994.
18. Smith, G. K., Banks, S. D., Bigham, E. C., Conn, N. K., Duch, D. S., Edelstein, M. P., Ferone, R., Hanlon, M. H., Heath, L. S., Humphreys, J., Kelley, J. L., Knick, V., McLean, E. W., Mullin, R. J., Singer, S., and Wilson, H. R. In vitro and in vivo activity of the GAR transformylase inhibitor 5-deazaacyclotetrahydrofolate. In: H-C., Curtius, S. Ghisla, and N. Blau (eds.), Chemistry and Biology of Pteridines: Pteridines and Folic Acid Derivatives, pp. 1015–1022. Berlin: Walter de Gruyter, 1990.
19. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, R. G. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J. Biol. Chem., 264: 328–333, 1989.
20. Kelley, J. L., McLean, E. W., Conn, N. K., Edelstein, M. P., Duch, D. S., Smith, G. K., Hanlon, M. H., and Ferone, R. Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, n-[4-[[3-(2,4-diammo-1,6-dmydro-OK)xo-5-pyrimidinyl)pro-pyl]amino]benzoyl]-L-glutamic acid. J. Med. Chem., 33: 561–567, 1990.
21. Keyomarsi, K., and Moran, R. G. Folinic acid augmentation of the effects of fluoropy-rimidines on murine and human leukemic cells. Cancer Res., 46: 5229–5235, 1986.
22. Keyomarsi, K., and Moran, R. G. Mechanism of the cytotoxic synergism of fluoro-pyrimidines and folinic acid in mouse leukemic cells. J. Biol. Chem., 263: 14402–14409, 1988.
23. Kennedy, D. G., Van den Berg, H. W., Clarke, R., and Murphy, R. F. The effect of leucovorin on the synthesis of methotrexate poly-gamma-glutamates in the MCF7 human breast cancer cell line. Biochem. Pharmacol., 34: 2897–2903, 1985.
24. Grindey, G. B., Alati, T., and Shih, C. Reversal of the toxicity but not antitumor activity of lomotrexol by folic acid. Proc. Am. Assoc. Cancer Res., 32: 324, 1991.
25. Wedge, S. R., Laohavinij, S., Taylor, G. A., Newell, D. R., Charlton, C. J., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Gumbrell, L., and Calvert, A. H. Modulation of lomotrexol toxicity by oral folic acid administration: a Phase I study. Proc. Am. Assoc. Cancer Res., 34: 274, 1993.
26. Bogden, A. E., Kelton, D. E., Cobb, W. R., and Esber, H. J. A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In: D. E. Houchens and A. Ovejera (eds.), Proceedings: Symposium on the Use of Athymic (Nude) Mice in Cancer Research, pp. 231–250. New York: Gustav Fisher, 1987.
27. Nottebrock, H., and Then, R. Thymidine concentrations in serum and urine of different animal species and man. Biochem. Pharmacol., 26: 2175–2179, 1977.
28. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects. Biochem. Pharmacol., 33: 3269–3275, 1984.
29. Erba, E., Sen, S., Vikhanskaya, F. L., and D'lncalci, M. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Br. J. Cancer, 69: 205–211, 1994.
30. Gaumont, Y., Kisliuk, R., Parsons, J. C., and Greco, W. R. Quantitation of folic acid enhancement of antifolate synergism. Cancer Res 52: 2228–2235, 1992.
31. Said, H. M., Ghishan, F. K., and Redha, R. Folate transport by human intestinal brush border membrane vesicles. Am. J. Physiol., 252: 229–236, 1987.
32. Sirotnak, F. M., Moccio, D. M., and Yang, C. H. Similar characteristics of folate analogue transport in vitro in contrast to dihydrofolate reductase levels in epithelial cells at different stages of maturation of mouse small intestine. Cancer Res., 44: 5204–5211, 1984.
33. Chello, P. L., Sirotnak, F. M., Dorick, D. M., and Donsbach, R. C. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in LI210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res., 37: 4297–303, 1977.
34. Zimmerman, J. Folic acid transport in organ-cultured mucosa of human intestines. Gastroenterology, 99: 964–972, 1990.
35. Rosenberg, I. H., Zimmerman, J., and Selhub, J. Folate transport. Chemioterapia, 4: 354–358, 1985.
36. Schron, C. M., pH modulation of the kinetics of rabbit jejunal, brush-border folate transport. J. Membr. Biol., 118: 259–267, 1990.
37. Zimmerman, J. Methotrexate transport in the human intestine: evidence for heterogeneity. Biochem. Pharmacol., 43: 2377–2383, 1992.
38. Zimmerman, J. Drug interactions in intestinal transport of folic acid and methotrexate: further evidence for the heterogeneity of folate transport in the human small intestine. Biochem. Pharmacol., 44: 1839–1842, 1992.
39. Henderson, G. B. Folate-binding proteins. Annu. Rev. Nutr., 10: 319–335, 1990.
40. Jansen, M., Dykstra, M., Lee, J. I., Stables, J., Topley, P., Knick, V. C., Mullin, R. J., Duch, D. S., and Smith, G. K. Effect of purine synthesis inhibition in WiDr spheroids in vitro or in WiDr or colon 38 tumors in vivo: complete growth inhibition but not regression. Biochem. Pharmacol., 47: 1067–1078, 1994.